Study investigates PROSE lenses as drug delivery device for patients with dry eye disease

News
Article

The study found that the prosthetic replacement of the ocular surface ecosystem lenses were well tolerated in the delivery of non-preserved cyclosporine 0.05%.

Image of PROSE lenses Image credit: BostonSight

Image credit: BostonSight

A recent study found that prosthetic replacement of the ocular surface ecosystem (PROSE) lenses as a drug delivery device for non-preserved cyclosporine 0.05% was well tolerated regarding ocular symptoms and ocular surface signs. The prospective observational pilot study’s purpose was to evaluate the tolerability of the lens in patients with dry eye syndrome, which was measured by evaluating OSDI scores, corneal and conjunctival staining, visual acuity, and conjunctival redness, in addition to administering a tolerability questionnaire.1

Although there was no statistically significant change in best corrected visual acuity when compared with placebo, there was statistically significant improvement without comparing with placebo (p < 0.05) in mean per subject and mean per eye corneal fluorescein staining, conjunctival lissamine staining, and conjunctival hyperemia by slit lamp examination at the 1 month followup.1

“Overall, minimal experience and literature exists regarding this drug delivery system and to our knowledge, this report is the first to ever describe a prospective clinical trial utilizing a pharmaceutical in this manner,” the study authors stated. “More specifically, no study has previously described results of a prospective clinical trial utilizing preservative-free cyclosporine 0.05% ophthalmic emulsion in a PROSE reservoir for the treatment of dry eye disease. The purpose of this pilot study is to provide an initial evaluation of tolerability of such a potential treatment.”

The study involved 14 participants that were enrolled over 14 months and evaluated by the same practitioner at 1 eye care center for the duration of the study. All participants were 18 years of age or older and had already been using or were willing to transition to buffered preservative-free normal saline (PuriLens, The Lifestyle Company) for the PROSE reservoir solution. Participants were also required to have a baseline corneal fluorescein staining of 2 or greater when combing the scores of both eyes.1

Participants instilled 1 drop of cyclosporine in the PROSE reservoir and then filled the reservoir with preservative-free normal saline. After wearing the lens for 6 hours, the reservoir was filled again and worn for another 4 hours. In the 1 month period, OSDI scores decreased by an average of 3.83 ± 6.87 from baseline (p = 0.07). Additionally, both National Eye Institute (NEI) corneal and conjunctival fluorescein staining scores improved (p< 0.05), but there was no statistically significant different responses across the five NEI corneal sections through ANOVA testing. There was also no statistically significant improvement in best corrected visual acuity. Additionally, average conjunctival redness found statistically significant improvement.1

The PROSE lens has been FDA approved as a highly customized scleral lens treatment indicated for management of conditions affects the ocular surface, including keratoconjunctivitis sicca, ocular graft-versus-host disease, neurotrophic keratitis, and Stevens-Johnson syndrome.1

Reference:

  1. Nakhla MN, Patel R, Crowley E, Li Y, Peiris TB, Brocks D. Utilizing PROSE as a drug delivery device for preservative-free cyclosporine 0.05% for the treatment of dry eye disease: A pilot study. Clin Ophthal. 2024;18:3203-3213. https://doi.org/10.2147/OPTH.S487369

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Dana Shannon, OD, FAAO, shares pearls on spotting red flags in need of referral and enhancing patient care with follow-up compliance.
Dana Shannon, OD, FAAO, detailed a lecture she gave at the NOA Midwestern Symposium earlier this month.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, gave 2 presentations alongside other ODs and MDs at CRU 2025.
Melissa Tawa, OD, FAAO, provides insights to take glaucoma management from reactive to proactive in presentations given at CRU 2025 in Napa, California.
Rachelle Lin, OD, MS, FAAO, details her presentation on inherited retinal diseases at CRU 2025.
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
© 2025 MJH Life Sciences

All rights reserved.